Bristol-Myers Squibb Company BMY said that its fourth-quarter revenues were $11.48 billion, up 1% Y/Y, beating the consensus of $11.19 billion, primarily due to higher sales of new product portfolio, as well as Eliquis and Opdivo, partially offset by lower sales of Revlimid.
U.S. revenues increased by 1% to $8.0 billion primarily due to higher sales of the new product portfolio, Eliquis and Opdivo, partially offset by lower sales of Revlimid.
Sales of Eliquis were $2.87 billion, up 7% from last year. Sales of Revlimid fell 36% to $1.45 billion in the quarter. Sales of its cancer immunotherapy Opdivo rose 8% to $2.39 billion.
The company’s adjusted EPS was $1.70, down 7% Y/Y, beating the consensus of $1.53.
Guidance: Bristol-Myers Squibb forecasts fiscal year 2024 adjusted EPS of $7.10-$7.40 versus consensus of $7.00.
Total 2024 revenues are expected to increase by low-single-digits; Excluding foreign exchange, total revenues are expected to increase by low single-digits.
Read Next: Medicare’s Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%.
In January, BofA Securities downgraded Bristol-Myers Squibb, noting that initially, the analyst believed that Bristol’s loss of exclusivity for drugs like Eliquis and Opdivo was widely understood, and it was anticipated that a new product lineup would compensate for these losses and boost market value.
Price Action: BMY shares are down 0.60% at $48.38 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.